

# Emilio Perucca

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/1774469/emilio-perucca-publications-by-citations.pdf>

**Version:** 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

279  
papers

22,067  
citations

66  
h-index

145  
g-index

324  
ext. papers

26,400  
ext. citations

6.9  
avg, IF

7.21  
L-index

#	Paper	IF	Citations
279	ILAE official report: a practical clinical definition of epilepsy. <i>Epilepsia</i> , <b>2014</b> , 55, 475-82	6.4	2408
278	Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. <i>Epilepsia</i> , <b>2010</b> , 51, 1069-77	6.4	2311
277	ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology. <i>Epilepsia</i> , <b>2017</b> , 58, 512-521	6.4	2084
276	Antiepileptic drugs--best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. <i>Epilepsia</i> , <b>2008</b> , 49, 1239-76	6.4	703
275	ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. <i>Epilepsia</i> , <b>2006</b> , 47, 1094-120	6.4	603
274	Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. <i>Lancet Neurology</i> , <b>2011</b> , 10, 609-17	24.1	546
273	Epilepsy: new advances. <i>Lancet</i> , <b>2015</b> , 385, 884-98	40	492
272	Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. <i>Epilepsia</i> , <b>2013</b> , 54, 551-63	6.4	467
271	Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. <i>CNS Drugs</i> , <b>2002</b> , 16, 695-714	6.7	454
270	Clinically relevant drug interactions with antiepileptic drugs. <i>British Journal of Clinical Pharmacology</i> , <b>2006</b> , 61, 246-55	3.8	420
269	Lennox-Gastaut syndrome: a consensus approach on diagnosis, assessment, management, and trial methodology. <i>Lancet Neurology</i> , <b>2009</b> , 8, 82-93	24.1	329
268	Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. <i>Lancet Neurology</i> , <b>2003</b> , 2, 347-56	24.1	321
267	Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. <i>Lancet Neurology</i> , <b>2003</b> , 2, 473-81	24.1	302
266	Idiosyncratic adverse reactions to antiepileptic drugs. <i>Epilepsia</i> , <b>2007</b> , 48, 1223-44	6.4	272
265	Development of new antiepileptic drugs: challenges, incentives, and recent advances. <i>Lancet Neurology</i> , <b>2007</b> , 6, 793-804	24.1	259
264	Clinically significant pharmacokinetic drug interactions with carbamazepine. An update. <i>Clinical Pharmacokinetics</i> , <b>1996</b> , 31, 198-214	6.2	236
263	The pharmacological treatment of epilepsy in adults. <i>Lancet Neurology</i> , <b>2011</b> , 10, 446-56	24.1	209

262	Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. <i>Lancet Neurology, The</i> , <b>2018</b> , 17, 530-538	24.1	202
261	Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy. <i>Epilepsia</i> , <b>2008</b> , 49, 1123-41	6.4	186
260	Determinants of health-related quality of life in pharmaco-resistant epilepsy: results from a large multicenter study of consecutively enrolled patients using validated quantitative assessments. <i>Epilepsia</i> , <b>2011</b> , 52, 2181-91	6.4	182
259	Identification of new epilepsy treatments: issues in preclinical methodology. <i>Epilepsia</i> , <b>2012</b> , 53, 571-82	6.4	171
258	Progress report on new antiepileptic drugs: a summary of the Eleventh Eilat Conference (EILAT XI). <i>Epilepsy Research</i> , <b>2013</b> , 103, 2-30	3	171
257	An international multicenter randomized double-blind controlled trial of lamotrigine and sustained-release carbamazepine in the treatment of newly diagnosed epilepsy in the elderly. <i>Epilepsia</i> , <b>2007</b> , 48, 1292-302	6.4	166
256	Pharmacologic Advantages of Antiepileptic Drug Monotherapy. <i>Epilepsia</i> , <b>1997</b> , 38, S6-S8	6.4	159
255	Interactions between antiepileptic drugs, and between antiepileptic drugs and other drugs. <i>Epileptic Disorders</i> , <b>2014</b> , 16, 409-31	1.9	151
254	Progress report on new antiepileptic drugs: A summary of the Twelfth Eilat Conference (EILAT XII). <i>Epilepsy Research</i> , <b>2015</b> , 111, 85-141	3	143
253	Birth defects after prenatal exposure to antiepileptic drugs. <i>Lancet Neurology, The</i> , <b>2005</b> , 4, 781-6	24.1	141
252	The new generation of antiepileptic drugs: advantages and disadvantages. <i>British Journal of Clinical Pharmacology</i> , <b>1996</b> , 42, 531-543	3.8	130
251	Relationship between adverse effects of antiepileptic drugs, number of coprescribed drugs, and drug load in a large cohort of consecutive patients with drug-refractory epilepsy. <i>Epilepsia</i> , <b>2010</b> , 51, 797-804	6.4	129
250	A pharmacological and clinical review on topiramate, a new antiepileptic drug. <i>Pharmacological Research</i> , <b>1997</b> , 35, 241-56	10.2	128
249	Cannabinoids in the Treatment of Epilepsy: Hard Evidence at Last?. <i>Journal of Epilepsy Research</i> , <b>2017</b> , 7, 61-76	1.8	125
248	Valproic acid after five decades of use in epilepsy: time to reconsider the indications of a time-honoured drug. <i>Lancet Neurology, The</i> , <b>2016</b> , 15, 210-218	24.1	123
247	Progress report on new antiepileptic drugs: a summary of the Tenth Eilat Conference (EILAT X). <i>Epilepsy Research</i> , <b>2010</b> , 92, 89-124	3	122
246	The long-term effect of vagus nerve stimulation on quality of life in patients with pharmaco-resistant focal epilepsy: the PuLSE (Open Prospective Randomized Long-term Effectiveness) trial. <i>Epilepsia</i> , <b>2014</b> , 55, 893-900	6.4	117
245	Adjunctive therapy versus alternative monotherapy in patients with partial epilepsy failing on a single drug: a multicentre, randomised, pragmatic controlled trial. <i>Epilepsy Research</i> , <b>2003</b> , 57, 1-13	3	114

244	Factors determining response to antiepileptic drugs in randomized controlled trials. A systematic review and meta-analysis. <i>Epilepsia</i> , <b>2011</b> , 52, 219-33	6.4	113
243	Is there a role for therapeutic drug monitoring of new anticonvulsants?. <i>Clinical Pharmacokinetics</i> , <b>2000</b> , 38, 191-204	6.2	113
242	The clinical pharmacokinetics of the newer antiepileptic drugs. Focus on topiramate, zonisamide and tiagabine. <i>Clinical Pharmacokinetics</i> , <b>1996</b> , 31, 29-46	6.2	107
241	Plasma protein binding of drugs in pregnancy. <i>Clinical Pharmacokinetics</i> , <b>1982</b> , 7, 336-52	6.2	104
240	Epilepsy, seizures, physical exercise, and sports: A report from the ILAE Task Force on Sports and Epilepsy. <i>Epilepsia</i> , <b>2016</b> , 57, 6-12	6.4	102
239	Antiepileptic drug therapy: does mechanism of action matter?. <i>Epilepsy and Behavior</i> , <b>2011</b> , 21, 331-41	3.2	101
238	Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia. <i>Psychopharmacology</i> , <b>2001</b> , 153, 238-43	4.7	101
237	Fetal exposure to GABA-acting antiepileptic drugs generates hippocampal and cortical dysplasias. <i>Epilepsia</i> , <b>2007</b> , 48, 684-93	6.4	100
236	An introduction to antiepileptic drugs. <i>Epilepsia</i> , <b>2005</b> , 46 Suppl 4, 31-7	6.4	100
235	The new generation of antiepileptic drugs: advantages and disadvantages. <i>British Journal of Clinical Pharmacology</i> , <b>1996</b> , 42, 531-43	3.8	100
234	Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. <i>Neurology</i> , <b>2015</b> , 85, 866-72	6.5	95
233	Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age. <i>Clinical Pharmacokinetics</i> , <b>2006</b> , 45, 351-63	6.2	93
232	Add-on phenytoin fails to prevent early seizures after surgery for supratentorial brain tumors: a randomized controlled study. <i>Epilepsia</i> , <b>2002</b> , 43, 175-82	6.4	92
231	Assessing risk to benefit ratio in antiepileptic drug therapy. <i>Epilepsy Research</i> , <b>2000</b> , 41, 107-39	3	92
230	Keeping people with epilepsy safe during the COVID-19 pandemic. <i>Neurology</i> , <b>2020</b> , 94, 1032-1037	6.5	91
229	Clinical significance of pharmacokinetic interactions between antiepileptic and psychotropic drugs. <i>Epilepsia</i> , <b>2002</b> , 43 Suppl 2, 37-44	6.4	91
228	Free fraction of valproic acid: in vitro time-dependent increase and correlation with free fatty acid concentration in human plasma and serum. <i>Epilepsia</i> , <b>1983</b> , 24, 65-73	6.4	90
227	Progress report on new antiepileptic drugs: A summary of the Fourteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIV). I. Drugs in preclinical and early clinical development. <i>Epilepsia</i> , <b>2018</b> , 59, 1811-1841	6.4	89

226	Lacosamide. <i>Nature Reviews Drug Discovery</i> , <b>2008</b> , 7, 973-4	64.1	84
225	Reversible pseudoatrophy of the brain and mental deterioration associated with valproate treatment. <i>Epilepsia</i> , <b>1998</b> , 39, 27-32	6.4	82
224	Inhibition of diazepam metabolism by fluvoxamine: a pharmacokinetic study in normal volunteers. <i>Clinical Pharmacology and Therapeutics</i> , <b>1994</b> , 56, 471-6	6.1	82
223	Progress report on new antiepileptic drugs: A summary of the Thirteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIII). <i>Epilepsia</i> , <b>2017</b> , 58, 181-221	6.4	78
222	Navigating toward fetal and maternal health: the challenge of treating epilepsy in pregnancy. <i>Epilepsia</i> , <b>2004</b> , 45, 1171-5	6.4	78
221	The clinical pharmacokinetics of the new antiepileptic drugs. <i>Epilepsia</i> , <b>1999</b> , 40 Suppl 9, S7-13	6.4	78
220	Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age: an update. <i>Clinical Pharmacokinetics</i> , <b>2013</b> , 52, 627-45	6.2	75
219	Diurnal fluctuations in free and total steady-state plasma levels of carbamazepine and correlation with intermittent side effects. <i>Epilepsia</i> , <b>1984</b> , 25, 476-81	6.4	74
218	What is the promise of new antiepileptic drugs in status epilepticus? Focus on brivaracetam, carisbamate, lacosamide, NS-1209, and topiramate. <i>Epilepsia</i> , <b>2009</b> , 50 Suppl 12, 49-50	6.4	71
217	Pharmacokinetic interactions with antiepileptic drugs. <i>Clinical Pharmacokinetics</i> , <b>1982</b> , 7, 57-84	6.2	68
216	Antiepileptic drugs and intrauterine death: A prospective observational study from EURAP. <i>Neurology</i> , <b>2015</b> , 85, 580-8	6.5	66
215	Harnessing the clinical potential of antiepileptic drug therapy: dosage optimisation. <i>CNS Drugs</i> , <b>2001</b> , 15, 609-21	6.7	66
214	Pharmacoresistance in Epilepsy. <i>CNS Drugs</i> , <b>1998</b> , 10, 171-179	6.7	66
213	Recommendations of the Italian League against Epilepsy working group on generic products of antiepileptic drugs. <i>Epilepsia</i> , <b>2006</b> , 47 Suppl 5, 16-20	6.4	65
212	Epilepsy priorities in Europe: A report of the ILAE-IBE Epilepsy Advocacy Europe Task Force. <i>Epilepsia</i> , <b>2015</b> , 56, 1687-95	6.4	64
211	Optimizing antiepileptic drug treatment in tumoral epilepsy. <i>Epilepsia</i> , <b>2013</b> , 54 Suppl 9, 97-104	6.4	61
210	Enantioselective pharmacokinetics of 10-hydroxycarbamazepine after oral administration of oxcarbazepine to healthy Chinese subjects. <i>Clinical Pharmacology and Therapeutics</i> , <b>1999</b> , 66, 547-53	6.1	60
209	Clinical pharmacokinetics of fluvoxamine. <i>Clinical Pharmacokinetics</i> , <b>1994</b> , 27, 175-90	6.2	56

208	Pharmacological and Therapeutic Properties of Cannabidiol for Epilepsy. <i>Drugs</i> , <b>2019</b> , 79, 1435-1454	12.1	55
207	Lacosamide: a new approach to target voltage-gated sodium currents in epileptic disorders. <i>CNS Drugs</i> , <b>2009</b> , 23, 555-68	6.7	55
206	Effect of levetiracetam on the pharmacokinetics of adjunctive antiepileptic drugs: a pooled analysis of data from randomized clinical trials. <i>Epilepsy Research</i> , <b>2005</b> , 64, 1-11	3	55
205	Identifying mutations in epilepsy genes: Impact on treatment selection. <i>Epilepsy Research</i> , <b>2019</b> , 152, 18-30	3	53
204	Monotherapy trials with the new antiepileptic drugs: study designs, practical relevance and ethical implications. <i>Epilepsy Research</i> , <b>1999</b> , 33, 247-62	3	52
203	The management of epilepsy in the 1990s. Acquisitions, uncertainties and priorities for future research. <i>Drugs</i> , <b>1995</b> , 49, 680-94	12.1	51
202	Teratogenicity of antiepileptic drugs. <i>Current Opinion in Neurology</i> , <b>2019</b> , 32, 246-252	7.1	51
201	Challenges in the clinical development of new antiepileptic drugs. <i>Pharmacological Research</i> , <b>2016</b> , 103, 95-104	10.2	50
200	Pharmacokinetic and metabolic investigation of topiramate disposition in healthy subjects in the absence and in the presence of enzyme induction by carbamazepine. <i>Epilepsia</i> , <b>2005</b> , 46, 378-84	6.4	50
199	A multicenter, randomized, placebo-controlled trial of levetiracetam in children and adolescents with newly diagnosed absence epilepsy. <i>Epilepsia</i> , <b>2011</b> , 52, 802-9	6.4	49
198	Clinical implications of hepatic microsomal enzyme induction by antiepileptic drugs <b>1987</b> , 33, 139-44		49
197	30 years of second-generation antiseizure medications: impact and future perspectives. <i>Lancet Neurology</i> , <b>2020</b> , 19, 544-556	24.1	48
196	Overtreatment in epilepsy: how it occurs and how it can be avoided. <i>CNS Drugs</i> , <b>2005</b> , 19, 897-908	6.7	48
195	Topiramate pharmacokinetics in children and adults with epilepsy: a case-matched comparison based on therapeutic drug monitoring data. <i>Clinical Pharmacokinetics</i> , <b>2005</b> , 44, 407-16	6.2	46
194	Increased apparent oral clearance of valproic acid during intake of combined contraceptive steroids in women with epilepsy. <i>Epilepsia</i> , <b>2006</b> , 47, 1569-72	6.4	46
193	Overtreatment in epilepsy: adverse consequences and mechanisms. <i>Epilepsy Research</i> , <b>2002</b> , 52, 25-33	3	46
192	Serum carbamazepine concentrations in elderly patients: a case-matched pharmacokinetic evaluation based on therapeutic drug monitoring data. <i>Epilepsia</i> , <b>2003</b> , 44, 923-9	6.4	46
191	Marketed new antiepileptic drugs: are they better than old-generation agents?. <i>Therapeutic Drug Monitoring</i> , <b>2002</b> , 24, 74-80	3.2	46

190	Plasma Protein Binding of Phenytoin in Health and Disease. <i>Therapeutic Drug Monitoring</i> , <b>1980</b> , 2, 331-344	42	46
189	Cardiac function and antiepileptic drug treatment in the elderly: a comparison between lamotrigine and sustained-release carbamazepine. <i>Epilepsia</i> , <b>2009</b> , 50, 1841-9	6.4	45
188	The new antiepileptic drugs: pharmacological and clinical aspects. <i>Current Pharmaceutical Design</i> , <b>2000</b> , 6, 839-60	3.3	44
187	Withdrawal of valproic acid treatment during pregnancy and seizure outcome: Observations from EURAP. <i>Epilepsia</i> , <b>2016</b> , 57, e173-7	6.4	43
186	Final safety, tolerability, and seizure outcomes in patients with focal epilepsy treated with adjunctive perampanel for up to 4 years in an open-label extension of phase III randomized trials: Study 307. <i>Epilepsia</i> , <b>2018</b> , 59, 866-876	6.4	42
185	Patterns of prescription of antiepileptic drugs in patients with refractory epilepsy at tertiary referral centres in Italy. <i>Epilepsy Research</i> , <b>2010</b> , 91, 273-82	3	42
184	Drug metabolism in pregnancy, infancy and childhood <b>1987</b> , 34, 129-43		42
183	Novel medications for epilepsy. <i>Drugs</i> , <b>2011</b> , 71, 2151-78	12.1	41
182	A functional polymorphism in the SCN1A gene does not influence antiepileptic drug responsiveness in Italian patients with focal epilepsy. <i>Epilepsia</i> , <b>2011</b> , 52, e40-4	6.4	41
181	The current state of epilepsy guidelines: A systematic review. <i>Epilepsia</i> , <b>2016</b> , 57, 13-23	6.4	39
180	Extended-release formulations of antiepileptic drugs: rationale and comparative value. <i>Epilepsy Currents</i> , <b>2009</b> , 9, 153-7	1.3	37
179	A prospective study of direct medical costs in a large cohort of consecutively enrolled patients with refractory epilepsy in Italy. <i>Epilepsia</i> , <b>2015</b> , 56, 1162-73	6.4	36
178	Stereoselective pharmacokinetic analysis of valnoctamide in healthy subjects and in patients with epilepsy. <i>Clinical Pharmacology and Therapeutics</i> , <b>1997</b> , 61, 442-9	6.1	36
177	CYP2C9 polymorphisms and phenytoin metabolism: implications for adverse effects. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2015</b> , 11, 1269-79	5.5	35
176	Antiepileptic drugs and brain maturation: fetal exposure to lamotrigine generates cortical malformations in rats. <i>Epilepsy Research</i> , <b>2008</b> , 78, 131-9	3	35
175	Influence of dosage, age, and co-medication on plasma topiramate concentrations in children and adults with severe epilepsy and preliminary observations on correlations with clinical response. <i>Therapeutic Drug Monitoring</i> , <b>2003</b> , 25, 700-8	3.2	35
174	Declining malformation rates with changed antiepileptic drug prescribing: An observational study. <i>Neurology</i> , <b>2019</b> , 93, e831-e840	6.5	34
173	The management of refractory idiopathic epilepsies. <i>Epilepsia</i> , <b>2001</b> , 42 Suppl 3, 31-5	6.4	34

172	From global campaign to global commitment: The World Health Assembly's Resolution on epilepsy. <i>Epilepsia</i> , <b>2015</b> , 56, 1651-7	6.4	32
171	Pharmacokinetic variability of new antiepileptic drugs at different ages. <i>Therapeutic Drug Monitoring</i> , <b>2005</b> , 27, 714-7	3.2	32
170	Pharmacokinetic profile of topiramate in comparison with other new antiepileptic drugs. <i>Epilepsia</i> , <b>1996</b> , 37 Suppl 2, S8-S13	6.4	32
169	Quantitative comparison of barbiturates in essential hand and head tremor. <i>Movement Disorders</i> , <b>1991</b> , 6, 65-8	7	32
168	Progress report on new antiepileptic drugs: A summary of the Fourteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIV). II. Drugs in more advanced clinical development. <i>Epilepsia</i> , <b>2018</b> , 59, 1842-1866	6.4	32
167	Antiepileptic drug selection for people with HIV/AIDS: evidence-based guidelines from the ILAE and AAN. <i>Epilepsia</i> , <b>2012</b> , 53, 207-14	6.4	31
166	Is a separate monotherapy indication warranted for antiepileptic drugs?. <i>Lancet Neurology</i> , <b>2015</b> , 14, 1229-40	24.1	30
165	Single-dose pharmacokinetics of lamotrigine in children: influence of age and antiepileptic comedication. <i>Therapeutic Drug Monitoring</i> , <b>2001</b> , 23, 217-22	3.2	30
164	Drug interactions with phenytoin. <i>Drugs</i> , <b>1981</b> , 21, 120-37	12.1	30
163	Critical Aspects Affecting Cannabidiol Oral Bioavailability and Metabolic Elimination, and Related Clinical Implications. <i>CNS Drugs</i> , <b>2020</b> , 34, 795-800	6.7	29
162	Characteristics of a large population of patients with refractory epilepsy attending tertiary referral centers in Italy. <i>Epilepsia</i> , <b>2010</b> , 51, 921-5	6.4	29
161	Influence of aging on serum phenytoin concentrations: a pharmacokinetic analysis based on therapeutic drug monitoring data. <i>Epilepsy Research</i> , <b>2004</b> , 59, 155-65	3	29
160	Eslicarbazepine Acetate 485-498		29
159	The pharmacogenomics of epilepsy. <i>Expert Review of Neurotherapeutics</i> , <b>2015</b> , 15, 1161-70	4.3	28
158	Does cannabidiol have antiseizure activity independent of its interactions with clobazam? An appraisal of the evidence from randomized controlled trials. <i>Epilepsia</i> , <b>2020</b> , 61, 1082-1089	6.4	28
157	What clinical trial designs have been used to test antiepileptic drugs and do we need to change them?. <i>Epileptic Disorders</i> , <b>2012</b> , 14, 124-31	1.9	28
156	Novel frontiers in epilepsy treatments: preventing epileptogenesis by targeting inflammation. <i>Expert Review of Neurotherapeutics</i> , <b>2013</b> , 13, 615-25	4.3	27
155	Development and validation of an HPLC-UV detection assay for the determination of rufinamide in human plasma and saliva. <i>Analytical and Bioanalytical Chemistry</i> , <b>2011</b> , 401, 1013-21	4.4	27



154	Interpretation of drug levels in acute and chronic disease states. <i>Clinical Pharmacokinetics</i> , <b>1985</b> , 10, 498-513	6.2	27
153	Italian consensus conference on epilepsy and pregnancy, labor and puerperium. <i>Epilepsia</i> , <b>2009</b> , 50 Suppl 1, 7-23	6.4	25
152	Designing clinical trials to assess antiepileptic drugs as monotherapy : difficulties and solutions. <i>CNS Drugs</i> , <b>2008</b> , 22, 917-38	6.7	24
151	Free concentration of carbamazepine and carbamazepine-10,11-epoxide in children and adults. Influence of age and phenobarbitone co-medication. <i>Clinical Pharmacokinetics</i> , <b>1985</b> , 10, 524-31	6.2	24
150	From clinical trials of antiepileptic drugs to treatment. <i>Epilepsia Open</i> , <b>2018</b> , 3, 220-230	4	24
149	The influence of old age and enzyme inducing comedication on the pharmacokinetics of valproic acid at steady-state: A case-matched evaluation based on therapeutic drug monitoring data. <i>Epilepsy Research</i> , <b>2006</b> , 70, 153-60	3	23
148	Plasma gabapentin concentrations in children with epilepsy: influence of age, relationship with dosage, and preliminary observations on correlation with clinical response. <i>Therapeutic Drug Monitoring</i> , <b>2003</b> , 25, 54-60	3.2	23
147	Mechanisms of Tolerance and Drug Resistance109-118		23
146	Pregabalin for the management of partial epilepsy. <i>Neuropsychiatric Disease and Treatment</i> , <b>2008</b> , 4, 1211-24	3.1	22
145	Changes in lamotrigine pharmacokinetics during pregnancy and the puerperium. <i>Therapeutic Drug Monitoring</i> , <b>2008</b> , 30, 544-7	3.2	22
144	Gender issues in antiepileptic drug treatment. <i>Neurobiology of Disease</i> , <b>2014</b> , 72 Pt B, 217-23	7.5	21
143	Off-label prescribing of antiepileptic drugs in pharmaco-resistant epilepsy: a cross-sectional drug utilization study of tertiary care centers in Italy. <i>CNS Drugs</i> , <b>2014</b> , 28, 939-49	6.7	21
142	Interlaboratory variability in the quantification of new generation antiepileptic drugs based on external quality assessment data. <i>Epilepsia</i> , <b>2003</b> , 44, 40-5	6.4	21
141	Not all that glitters is gold: A guide to the critical interpretation of drug trials in epilepsy. <i>Epilepsia Open</i> , <b>2016</b> , 1, 9-21	4	20
140	Sertraline-induced potentiation of the CYP3A4-dependent neurotoxicity of carbamazepine: an in vitro study. <i>Epilepsia</i> , <b>2015</b> , 56, 439-49	6.4	19
139	New and forthcoming anti-epileptic drugs. <i>Current Opinion in Neurology</i> , <b>2011</b> , 24, 159-64	7.1	19
138	Age-related changes in pharmacokinetics: predictability and assessment methods. <i>International Review of Neurobiology</i> , <b>2007</b> , 81, 183-99	4.4	19
137	Free and total serum concentrations of carbamazepine and carbamazepine-10,11-epoxide in infancy and childhood. <i>Epilepsia</i> , <b>1985</b> , 26, 320-2	6.4	19

136	Influence of enzyme inducing antiepileptic drugs on the pharmacokinetics of levetiracetam in patients with epilepsy. <i>Epilepsy Research</i> , <b>2011</b> , 94, 117-20	3	18
135	Current trends in antiepileptic drug therapy. <i>Epilepsia</i> , <b>2003</b> , 44 Suppl 4, 41-7	6.4	18
134	Progress report on new antiepileptic drugs: A summary of the Fifteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XV). II. Drugs in more advanced clinical development. <i>Epilepsia</i> , <b>2020</b> , 61, 2365-2385	6.4	18
133	Cannabidiol in the treatment of epilepsy: Current evidence and perspectives for further research. <i>Neuropharmacology</i> , <b>2021</b> , 185, 108442	5.5	18
132	Low risk pragmatic trials do not always require participants' informed consent. <i>BMJ, The</i> , <b>2019</b> , 364, l10929	3.9	17
131	Developing clinical practice guidelines for epilepsy: A report from the ILAE Epilepsy Guidelines Working Group. <i>Epilepsia</i> , <b>2015</b> , 56, 1859-69	6.4	17
130	A novel enantioselective microassay for the high-performance liquid chromatography determination of oxcarbazepine and its active metabolite monohydroxycarbazepine in human plasma. <i>Therapeutic Drug Monitoring</i> , <b>2007</b> , 29, 319-24	3.2	17
129	Old versus new antiepileptic drugs: the SANAD study. <i>Lancet, The</i> , <b>2007</b> , 370, 313; author reply 315-6	4.0	17
128	Recent advances in the diagnosis and treatment of epilepsy. <i>European Journal of Neurology</i> , <b>2001</b> , 8, 519-39	6	17
127	ILAE-Klassifikation der Epilepsien: Positionspapier der ILAE-Kommission für Klassifikation und Terminologie. <i>Zeitschrift Für Epileptologie</i> , <b>2018</b> , 31, 296-306	0.1	17
126	Novel therapies for epilepsy in the pipeline. <i>Epilepsy and Behavior</i> , <b>2019</b> , 97, 282-290	3.2	16
125	When clinical trials make history: demonstrating efficacy of new antiepileptic drugs as monotherapy. <i>Epilepsia</i> , <b>2010</b> , 51, 1933-5	6.4	16
124	Newer and Older Antidepressants. <i>CNS Drugs</i> , <b>1994</b> , 2, 479-497	6.7	16
123	ILAE classification and definition of epilepsy syndromes with onset in neonates and infants: Position statement by the ILAE Task Force on Nosology and Definitions.. <i>Epilepsia</i> , <b>2022</b> ,	6.4	15
122	Stereoselective determination of vigabatrin enantiomers in human plasma by high performance liquid chromatography using UV detection. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , <b>2007</b> , 854, 63-7	3.2	14
121	Maternal and fetal outcomes associated with vagus nerve stimulation during pregnancy. <i>Epilepsy Research</i> , <b>2017</b> , 137, 159-162	3	13
120	The impact of enzyme-inducing antiepileptic drugs on antiretroviral drug levels: a case-control study. <i>Epilepsy Research</i> , <b>2013</b> , 103, 245-53	3	13
119	Evaluation of drug treatment outcome in epilepsy: a clinical perspective. <i>International Journal of Clinical Pharmacy</i> , <b>1997</b> , 19, 217-22		13

118	Epilepsy care during the COVID-19 pandemic. <i>Epilepsia</i> , <b>2021</b> , 62, 2322-2332	6.4	13
117	Invasive EEG in Presurgical Evaluation of Epilepsy 767-798		13
116	Time to Start Calling Things by Their Own Names? The Case for Antiseizure Medicines. <i>Epilepsy Currents</i> , <b>2020</b> , 20, 69-72	1.3	12
115	Prenatal exposure to antiepileptic drugs. <i>Lancet, The</i> , <b>2006</b> , 367, 1467-9	4.0	12
114	International League Against Epilepsy classification and definition of epilepsy syndromes with onset in childhood: Position paper by the ILAE Task Force on Nosology and Definitions.. <i>Epilepsia</i> , <b>2022</b> ,	6.4	12
113	Commentary: Epilepsy is a Global Problem. <i>Epilepsia</i> , <b>2014</b> , 55, 1326-8	6.4	11
112	What can we learn from clinical trials of anticonvulsant drugs in epilepsy?. <i>European Journal of Pain</i> , <b>2002</b> , 6 Suppl A, 35-44	3.7	11
111	In vivo plasma protein binding interaction between valproic acid and naproxen. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , <b>1984</b> , 9, 359-63	2.7	11
110	A pragmatic algorithm to select appropriate antiseizure medications in patients with epilepsy. <i>Epilepsia</i> , <b>2020</b> , 61, 1668-1677	6.4	11
109	FDA safety warning on the cardiac effects of lamotrigine: An advisory from the Ad Hoc ILAE/AES Task Force. <i>Epilepsia Open</i> , <b>2021</b> , 6, 45-48	4	11
108	Neurovascular Drug Biotransformation Machinery in Focal Human Epilepsies: Brain CYP3A4 Correlates with Seizure Frequency and Antiepileptic Drug Therapy. <i>Molecular Neurobiology</i> , <b>2019</b> , 56, 8392-8407	6.2	10
107	Seizure-alerting behavior in dogs owned by people experiencing seizures. <i>Epilepsy and Behavior</i> , <b>2019</b> , 94, 104-111	3.2	10
106	2017 International League Against Epilepsy classifications of seizures and epilepsy are steps in the right direction. <i>Epilepsia</i> , <b>2019</b> , 60, 1040-1044	6.4	9
105	Validated outcome of treatment changes according to International League Against Epilepsy criteria in adults with drug-resistant focal epilepsy. <i>Epilepsia</i> , <b>2019</b> , 60, 1114-1123	6.4	9
104	Antiepileptic drug use and epileptic seizures in nursing home residents in the Province of Pavia, Italy: A reappraisal 12 years after a first survey. <i>Epilepsy Research</i> , <b>2016</b> , 119, 41-8	3	9
103	Availability of antiepileptic drugs across Europe. <i>Epilepsia</i> , <b>2015</b> , 56, e191-7	6.4	9
102	Translating monotherapy trials into clinical practice: a look into the abyss. <i>Epilepsy and Behavior</i> , <b>2003</b> , 4, 457-63	3.2	9
101	Trials in the elderly. <i>Epilepsy Research</i> , <b>2001</b> , 45, 149-51; discussion 153-4	3	9

100	The Interplay Between Liver First-Pass Effect and Lymphatic Absorption of Cannabidiol and Its Implications for Cannabidiol Oral Formulations. <i>Clinical Pharmacokinetics</i> , <b>2020</b> , 59, 1493-1500	6.2	9
99	The ideal pharmacokinetic properties of an antiepileptic drug: how close does levetiracetam come?. <i>Epileptic Disorders</i> , <b>2003</b> , 5 Suppl 1, S17-26	1.9	9
98	Rapid onset of seizure suppression with pregabalin adjunctive treatment in patients with partial seizures. <i>Epilepsia</i> , <b>2009</b> , 50, 1891-8	6.4	8
97	Antiepileptic drugs: evolution of our knowledge and changes in drug trials <b>2019</b> , 21, 319-329		8
96	Novel study design to assess the efficacy and tolerability of antiseizure medications for focal-onset seizures in infants and young children: A consensus document from the regulatory task force and the pediatric commission of the International League against Epilepsy (ILAE), in collaboration with the Pediatric Epilepsy Research Consortium (PERC). <i>Epilepsia Open</i> , <b>2019</b> , 4, 537-543	4	7
95	Do neurologists agree in diagnosing drug resistance in adults with focal epilepsy?. <i>Epilepsia</i> , <b>2019</b> , 60, 175-183	6.4	7
94	Optimal choice of antiseizure medication: Agreement among experts and validation of a web-based decision support application. <i>Epilepsia</i> , <b>2021</b> , 62, 220-227	6.4	7
93	Brivaracetam 447-457		6
92	The treatment of the first seizure: the risks. <i>Epilepsia</i> , <b>2008</b> , 49 Suppl 1, 29-34	6.4	6
91	Antiepileptic Drug Teratogenicity and De Novo Genetic Variation Load. <i>Annals of Neurology</i> , <b>2020</b> , 87, 897-906	9.4	5
90	When the past challenges the present: are older antiepileptic drugs still the best choice in childhood absence epilepsy?. <i>Lancet Neurology</i> , <b>2010</b> , 9, 457-9	24.1	5
89	Predictability of metabolic antiepileptic drug interactions <b>2005</b> , 57-92		5
88	Does screening for adverse effects improve health outcomes in epilepsy? A randomized trial. <i>Neurology</i> , <b>2020</b> , 95, e239-e246	6.5	4
87	No Evidence of a Causal Role of Antiepileptic Drug Treatment with Regard to the Development of Dementia. <i>Journal of the American Geriatrics Society</i> , <b>2018</b> , 66, 1850-1852	5.6	4
86	Epilepsy: seizures, syndromes, and survival. <i>Lancet Neurology</i> , <b>2009</b> , 8, 10-2	24.1	4
85	Patient-tailored antiepileptic drug therapy: predicting response to antiepileptic drugs. <i>International Congress Series</i> , <b>2002</b> , 1244, 93-103		4
84	A simple and rapid HPLC-UV method for the determination of retigabine in human plasma. <i>Biomedical Chromatography</i> , <b>2018</b> , 32, e4168	1.7	4
83	No proof of a causal relationship between antiepileptic drug treatment and incidence of dementia. Comment on: Use of antiepileptic drugs and dementia risk-An analysis of Finnish health register and German health insurance data. <i>Epilepsia</i> , <b>2018</b> , 59, 1303-1306	6.4	4

82	Fenfluramine repurposing from weight loss to epilepsy: What we do and do not know. <i>Pharmacology &amp; Therapeutics</i> , <b>2021</b> , 226, 107866	13.9	4
81	Interpretation of drug levels: relevance of plasma protein binding. <i>Novartis Foundation Symposium</i> , <b>1979</b> , 51-68		4
80	Rufinamide647-655		4
79	Methodology for classification and definition of epilepsy syndromes with list of syndromes: Report of the ILAE Task Force on Nosology and Definitions.. <i>Epilepsia</i> , <b>2022</b> ,	6.4	4
78	The safety of generic substitution in epilepsy. <i>Lancet Neurology, The</i> , <b>2016</b> , 15, 344-5	24.1	3
77	Classification as autonomic versus sensory seizures. <i>Epilepsia</i> , <b>2019</b> , 60, 2003-2005	6.4	3
76	How long for epilepsy remission in the ILAE definition?. <i>Epilepsia</i> , <b>2017</b> , 58, 1486-1487	6.4	3
75	Changes in plasma levetiracetam concentrations in pregnant women and their breastfed infants. <i>Nature Clinical Practice Neurology</i> , <b>2007</b> , 3, 538-9		3
74	Active control trials: endpoints beyond conventional efficacy and tolerability measures. <i>Epilepsy Research</i> , <b>2006</b> , 68, 73-4	3	3
73	Trial duration and follow-up. <i>Epilepsy Research</i> , <b>2001</b> , 45, 123-7; discussion 129-31	3	3
72	Psychiatric Features of Epilepsy and their Management273-287		3
71	Pyridoxine supplementation for levetiracetam-related neuropsychiatric adverse events: A systematic review. <i>Epilepsy and Behavior</i> , <b>2020</b> , 103, 106861	3.2	3
70	Determination of Perampanel in Dried Plasma Spots: Applicability to Therapeutic Drug Monitoring. <i>Therapeutic Drug Monitoring</i> , <b>2020</b> , 42, 309-314	3.2	3
69	Corticosteroids versus clobazam in epileptic encephalopathy with ESES: a European multicentre randomised controlled clinical trial (RESCUE ESES*). <i>Trials</i> , <b>2020</b> , 21, 957	2.8	3
68	An investigation of the influence of patient-related factors and comedications on lamotrigine clearance in patients with epilepsy. <i>Clinical and Experimental Pharmacology and Physiology</i> , <b>2016</b> , 43, 685-9	3	3
67	Basal Ganglia Dysmorphism in Patients With Aicardi Syndrome. <i>Neurology</i> , <b>2021</b> , 96, e1319-e1333	6.5	3
66	Drug interactions with carbamazepine: An ever expanding list?. <i>Epilepsy Research</i> , <b>2018</b> , 147, 119-120	3	3
65	Epidemiology and Prognosis of Epilepsy21-31		3

64	Phenobarbital, Primidone and Other Barbiturates585-603		3
63	Retigabine637-646		3
62	Mechanisms of Antiepileptic Drug Action91-108		3
61	Commentary: why an international epilepsy day?. <i>Epilepsia</i> , <b>2015</b> , 56, 170-1	6.4	2
60	EURAP registry: inadequate monitoring of prescribed drugs in pregnancy - Authors' reply. <i>Lancet Neurology, The</i> , <b>2018</b> , 17, 741-742	24.1	2
59	Advocacy for children with epilepsy: Leveraging the WHA resolution. Advocacy Task Force, Commission of Pediatrics, International League Against Epilepsy. <i>Epilepsia Open</i> , <b>2018</b> , 3, 167-174	4	2
58	Brivaracetam <b>2015</b> , 418-430		2
57	Management of Side-Effects of Antiepileptic Drugs289-299		2
56	Mechanisms of Epileptogenesis67-79		2
55	Pregabalin as Adjunctive Treatment of Partial Seizures. <i>CNS Drugs</i> , <b>2005</b> , 19, 273-274	6.7	2
54	Principles of pharmacotherapy of the epilepsies <b>2002</b> , 1301-1312		2
53	Pediatric adverse reactions to antiseizure medications - An analysis of data from the Italian spontaneous reporting system (2001-2019). <i>Epilepsy and Behavior</i> , <b>2021</b> , 119, 107989	3.2	2
52	The initial impact of the SARS-CoV-2 pandemic on epilepsy research. <i>Epilepsia Open</i> , <b>2021</b> , 6, 255-265	4	2
51	A web-based algorithm to rapidly classify seizures for the purpose of drug selection. <i>Epilepsia</i> , <b>2021</b> , 62, 2474-2484	6.4	2
50	Selection of antiseizure medications for first add-on use: A consensus paper. <i>Epilepsy and Behavior</i> , <b>2021</b> , 122, 108087	3.2	2
49	Introduction to the Choice of Antiepileptic Drugs365-375		2
48	Aetiology of Epilepsy33-53		2
47	Benzodiazepines used Primarily for Emergency Treatment (Diazepam, Lorazepam and Midazolam)431-446		2

46	Ethosuximide499-509		2
45	MRI in the Presurgical Evaluation805-820		2
44	Vagal Nerve Stimulation1017-1023		2
43	A Tribute to Steve White. <i>Neurochemical Research</i> , <b>2017</b> , 42, 1867-1868	4.6	1
42	Management of Epilepsy in People with Learning Disabilities219-229		1
41	General Principles of Medical Management119-139		1
40	Management of Chronic Active Epilepsy in Adults153-162		1
39	Management of Childhood Epilepsy Syndromes179-194		1
38	Withdrawing antiepileptic drugs in seizure-free patients: what are the cognitive benefits?. <i>Nature Clinical Practice Neurology</i> , <b>2007</b> , 3, 194-5		1
37	Diurnal Fluctuations in Free and Total Plasma Concentrations of Carbamazepine at Steady-State and Correlation with Intermittent Side Effects in Epileptic Patients. <i>Clinical Pharmacokinetics</i> , <b>1984</b> , 9, 93-94	6.2	1
36	Lorcaserin for Dravet Syndrome: A Potential Advance Over Fenfluramine?. <i>CNS Drugs</i> , <b>2022</b> , 36, 113	6.7	1
35	Web-based decision support system for patient-tailored selection of antiseizure medication in adolescents and adults: An external validation study. <i>European Journal of Neurology</i> , <b>2021</b> , 29, 382	6	1
34	Management of Newly Diagnosed Epilepsy141-151		1
33	Management of Epilepsies Associated with Specific Diseases in Children195-201		1
32	Felbamate511-518		1
31	Perampanel as first add-on antiseizure medication: Italian consensus clinical practice statements. <i>BMC Neurology</i> , <b>2021</b> , 21, 410	3.1	1
30	New paradigms for the treatment of pediatric monogenic epilepsies: Progressing toward precision medicine. <i>Epilepsy and Behavior</i> , <b>2021</b> , 107961	3.2	1
29	Bioequivalence and switchability of generic antiseizure medications (ASMs): A re-appraisal based on analysis of generic ASM products approved in Europe. <i>Epilepsia</i> , <b>2021</b> , 62, 285-302	6.4	1

28	Traumatic Brain Injury and Other Risks249-257		1
27	Medical Treatment of Epilepsy in Situations with Limited Resources379-385		1
26	Introduction to the Choice of Antiepileptic Drugs387-398		1
25	Adrenocorticotrophic Hormone and Corticosteroids411-419		1
24	Differential Diagnosis of Epilepsy55-66		1
23	Antiepileptic Drug Discovery81-89		1
22	Experimental Neurophysiological Techniques829-849		1
21	Neuropsychological Testing in Presurgical Evaluation851-863		1
20	Can drug resistance in epilepsy be minimized? Challenging commonly held beliefs. <i>Epileptic Disorders</i> , <b>2005</b> , 7 Suppl 1, S14-21	1.9	1
19	Relationship between saliva and plasma rufinamide concentrations in patients with epilepsy. <i>Epilepsia</i> , <b>2020</b> , 61, e79-e84	6.4	0
18	Reproductive Aspects of Epilepsy Treatment323-333		0
17	Management of Epilepsy in Infants171-178		0
16	Emergency Treatment of Seizures and Status Epilepticus231-247		0
15	Management of Epilepsy in Remission163-169		0
14	Management of Epilepsy in the Elderly203-217		0
13	Management of Medical Co-morbidity Associated with Epilepsy259-272		0
12	Ketogenic Diets301-310		0
11	Non-pharmacological, Complementary and Alternative Treatments for Epilepsy311-322		0



10	Epilepsy Counselling335-340		0
9	Genetic Counselling in Epilepsy341-360		0
8	Carisbamate475-484		0
7	The EpiPick algorithm to select appropriate antiseizure medications in patients with epilepsy: Validation studies and updates. <i>Epilepsia</i> , <b>2021</b> ,	6.4	0
6	Response: Cannabidiol antiseizure activity and its interactions with clobazam: "It's dJvu all over again" Yogi Berra. <i>Epilepsia</i> , <b>2020</b> , 61, 1793-1794	6.4	
5	Pharmacokinetic Optimization of Therapy <b>2015</b> , 124-138		
4	General Principles of Medical Management <b>2015</b> , 110-123		
3	Drug interactions in epilepsy. <i>Arquivos De Neuro-Psiquiatria</i> , <b>1980</b> , 38, 331-40	1.6	
2	A young woman with recurring seizures. <i>Neurosciences</i> , <b>2011</b> , 16, 292-4	0.1	
1	The 50th anniversary of the Italian League against epilepsy (Lega Italiana Contro l'Epilessia). <i>Epilepsy and Behavior Reports</i> , <b>2022</b> , 19, 100553	1.3	